Pomalidomide Teva

/ Teva Israel LTD, Israel

Pomalidomide in combination with bortezomib and dexamethasone
The recommended starting dose of pomalidomide is 4 mg taken orally once daily on Days 1 to 14 of repeated 21-day cycles.
Treatment with pomalidomide combined with bortezomib and dexamethasone should be given until disease progression or until unacceptable toxicity occurs.
Pomalidomide in combination with dexamethasone
The recommended starting dose of pomalidomide is 4 mg taken orally once daily on Days 1 to 21 of each 28-day cycle.
Treatment with pomalidomide combined with dexamethasone should be given until disease progression or until unacceptable toxicity occurs.
Please refer to the license holder for further details.

Pomalidomide in combination with dexamethasone
Treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Pomalidomide in combination with bortezomib and dexamethasone
Treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

* Pregnancy.
* Women of childbearing potential, unless all the conditions of the Imnovid Risk Management Program – Pregnancy Prevention Program (RMP-PPP) are met.
* Male patients unable to follow or comply with the required contraceptive measures.
* Hypersensitivity to the active substance or to any of the excipients.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.